This website is for UK and Ireland Healthcare professionals only.

If you are not a healthcare professional in the UK, please click here.

If you are not a healthcare professional in Ireland, please click here.

Eliquis® (apixaban)

Risk Minimisation Information for Healthcare Professionals

Therapeutic indication: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1

Dosing recommendations

The recommended dose of apixaban is 2.5 mg taken orally twice daily with water, with or without food. The initial dose should be taken 12 to 24 hours after surgery.

Physicians may consider the potential benefits of earlier anticoagulation for VTE prophylaxis as well as the risks of post-surgical bleeding in deciding on the time of administration within this time window.

In patients undergoing hip replacement surgery, the recommended duration of treatment is 32 to 38 days.

In patients undergoing knee replacement surgery, the recommended duration of treatment is 10 to 14 days.

For patients who are unable to swallow whole tablets, apixaban tablets may be crushed and suspended in water, or 5% glucose in water (G5W), or apple juice or mixed with apple puree and immediately administered orally. Alternatively, apixaban tablets may be crushed and suspended in 60 mL of water or G5W and immediately delivered through a nasogastric tube. Crushed apixaban tablets are stable in water, G5W, apple juice, and apple puree for up to 4 hours.

Missed dose

If a dose is missed, the patient should take apixaban immediately and then continue with twice daily intake as before.

Click below for information on use in specific patient populations.

Renal impairment  
Dialysis Not recommended
Renal failure
(CrCl <15 ml/min)
Not recommended
Severe renal impairment (CrCl 15–29 ml/min) Use with caution
Mild (CrCl 51–80 ml/min) or moderate (CrCl 30–50 ml/min) renal impairment No dose adjustment required

This Prescriber Guide is not a substitute for the apixaban Summary of Product Characteristics (SmPC). Please consult the SmPC for full prescribing information.